Clinical Trial Update: Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 pilot study investigating LDN and NAD+ for post-COVID-19 syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long COVID-19
• Post-covid-19 Syndrome

Drugs mentioned

• LDN (low-dose naltrexone)
• NAD+ (nicotinamide adenine dinucleotide)

Snippet

Sponsor: AgelessRx | Conditions: Covid19, Long COVID-19 | Phase 2 | Status: COMPLETED